UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of |
(Commission |
(IRS Employer |
incorporation) |
File Number) |
Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, include area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 6, 2023, in order to achieve an equal balance of membership among the classes of directors, the board of directors (the “Board”) of SQZ Biotechnologies Company (the “Company”) determined to move one of the directors from Class I with a term expiring at the 2024 annual meeting of shareholders to Class III with a term expiring at the 2023 annual meeting of shareholders. Accordingly, on April 6, 2023, Howard Bernstein, M.D., Ph.D., who was a Class I director, resigned as a director and was immediately elected by the Board as a Class III director. The resignation and re-election of Dr. Bernstein was effected solely to rebalance the Board's classes and, for all other purposes, Dr. Bernstein’s service on the Board is deemed to have continued uninterrupted. The Board now consists of three Class I directors, four Class II directors and three Class III directors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
SQZ BIOTECHNOLOGIES COMPANY |
|
|
|
|
Date: April 10, 2023 |
By: |
/s/ Lawrence Knopf |
|
|
Lawrence Knopf |
|
|
General Counsel |
Document And Entity Information |
Apr. 06, 2023 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Apr. 06, 2023 |
| Entity Registrant Name | SQZ BIOTECHNOLOGIES COMPANY |
| Entity Central Index Key | 0001604477 |
| Entity Emerging Growth Company | true |
| Securities Act File Number | 001-39662 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 46-2431115 |
| Entity Address, Address Line One | 200 Arsenal Yards Blvd |
| Entity Address, Address Line Two | Suite 210 |
| Entity Address, City or Town | Watertown |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02472 |
| City Area Code | 617 |
| Local Phone Number | 758-8672 |
| Entity Information, Former Legal or Registered Name | N/A |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Ex Transition Period | false |
| Title of 12(b) Security | Common Stock, par value $0.001 per share |
| Trading Symbol | SQZ |
| Security Exchange Name | NYSE |